Investor Relations

About AVROBIO

 

Our vision is to bring personalized gene therapy to the world. We aim to prevent, halt or reverse disease throughout the body with a single dose of gene therapy designed to drive durable expression of functional protein, even in hard-to-reach tissues and organs including the brain, muscle and bone. Our ex vivo lentiviral gene therapy pipeline includes clinical programs in Fabry disease, Gaucher disease type 1 and cystinosis, as well as preclinical programs in Hunter syndrome, Gaucher disease type 3 and Pompe disease. AVROBIO is powered by its industry leading plato® gene therapy platform, our foundation designed to deliver gene therapy worldwide. We are headquartered in Cambridge, Mass., with an office in Toronto, Ontario.

 

Sign up for email alerts

Stock Chart


Data Provided by Refinitiv. Minimum 15 minutes delayed.

Events & Presentations

Our News Latest press releases

Jan 22, 2021

AVROBIO to Present at the Cowen 2021 Gene Therapy: CMC & Regulatory Summit

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 22, 2021-- AVROBIO, Inc. (Nasdaq:AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced Azadeh Golipour, VP of Manufacturing Operations at AVROBIO , will present virtually at the

Read More

Jan 19, 2021

AVROBIO Announces the Appointment of Diana M. Escolar, M.D. as Chief Medical Officer

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 19, 2021-- AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced the appointment of Diana M. Escolar, M.D., FAAN, as chief medical officer. Dr.

Read More

Jan 08, 2021

AVROBIO to Present at the ICR Conference 2021

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 8, 2021-- AVROBIO , Inc. (NASDAQ: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced Geoff MacKay , president and CEO of AVROBIO , will present virtually at the ICR

Read More

See All

Investors & Media Sign up for
Email Alerts

We’ll keep you connected to the latest news about AVROBIO’s research and pipeline.